Review
Prostate Cancer and Prostatic Diseases advance online publication 3 June 2008; doi: 10.1038/pcan.2008.32
Prostate cancer chemotherapy in the era of targeted therapy
A Michael1, K Syrigos2 and H Pandha1
- 1Oncology Department, Postgraduate Medical School, University of Surrey, Surrey, UK
- 2Oncology Unit, Third Department of Medicine, Sotiria General Hospital, Athens University School of Medicine, Athens, Greece
Correspondence: Dr A Michael, Department of Oncology, Postgraduate Medical School, University of Surrey, Daphne Jackson Road, Manor Park, Guildford, Surrey GU2 7WG, UK. E-mail: a.michael@surrey.ac.uk
Received 10 April 2008; Accepted 5 May 2008; Published online 3 June 2008.
Abstract
Prostate cancer is the most common cancer in men accounting for around 24% of all male cancers in United Kingdom. The role of chemotherapy in the neoadjuvant and adjuvant setting is still unclear despite considerable progress in this area. Chemotherapy for advanced prostate cancer has become the standard of care, however options of treatment following taxotere failure are still limited. This review summarizes recent advances in chemotherapy treatment options for early as well as advanced prostate cancer.
Keywords:
chemotherapy, PSA, targeted therapy